ArticleEClinicalMedicine2026
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06805812 (Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endocrine therapy (ET) plus Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i) is the recommended first-line treatment for patients with Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative advanced Breast Cancer (HR+/HER2- aBC). The prognostic value of the spectrum of Oestrogen Receptor (ERα) and Progesterone receptor (PgR) expression remains poorly investigated in this setting. Methods: We used updated data from the largest annotated dataset from the multicentre, real-world, Italian study PALMARES-2 (NCT06805812) to evaluate the association between ERα expression and real-world Progression-Free Survival (rwPFS), or time-to-chemotherapy (rwTTC), in patients with HR+/HER2- aBC treated with first-line ET plus CDK4/6/i. ERα expression was classified as low-intermediate (LI: 1-49%), high (H: 50-89%) or very-high (VH: 90-100%). We also assessed the prognostic value of combining PgR (<20% vs. ≥20%) and ERα expression. Multivariable Cox regression models were used to adjust associations for clinically relevant covariates. Findings: Among 4115 patients with available ERα assessment, 157 (3.8%) had ER-LI, 967 (23.5%) had ER-H and 2991 (72.7%) had ER-VH tumours. Median rwPFS and rwTTC increased progressively with increasing ERα expression (ER-LI: 10.6 and 14.3 months; ER-H: 20.5 and 29.9 months; ER-VH: 28.5 and 40.7 months, respectively; p < 0.001). PgR expression provided additional prognostic stratification, with patients with ER-VH/PgR-high tumours showing the longest median rwPFS (32.4 months, 95% CI 30.2-34.9), while those with ER-LI/PgR-low tumours had the shortest (8.3 months; 95% CI 6.9-12). Interpretation: Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2- aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes. Our findings, if confirmed by future studies, can help clinicians in personalising treatment choices and follow-up strategies in this clinical context. Funding: PALMARES-2 is an academic investigator-initiated study partially supported by AstraZeneca/Daiichi Sankyo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.